» Articles » PMID: 33091374

Estimating the Infection-fatality Risk of SARS-CoV-2 in New York City During the Spring 2020 Pandemic Wave: a Model-based Analysis

Overview
Date 2020 Oct 22
PMID 33091374
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Background: As the COVID-19 pandemic continues to unfold, the infection-fatality risk (ie, risk of death among all infected individuals including those with asymptomatic and mild infections) is crucial for gauging the burden of death due to COVID-19 in the coming months or years. Here, we estimate the infection-fatality risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City, NY, USA, the first epidemic centre in the USA, where the infection-fatality risk remains unclear.

Methods: In this model-based analysis, we developed a meta-population network model-inference system to estimate the underlying SARS-CoV-2 infection rate in New York City during the 2020 spring pandemic wave using available case, mortality, and mobility data. Based on these estimates, we further estimated the infection-fatality risk for all ages overall and for five age groups (<25, 25-44, 45-64, 65-74, and ≥75 years) separately, during the period March 1 to June 6, 2020 (ie, before the city began a phased reopening).

Findings: During the period March 1 to June 6, 2020, 205 639 people had a laboratory-confirmed infection with SARS-CoV-2 and 21 447 confirmed and probable COVID-19-related deaths occurred among residents of New York City. We estimated an overall infection-fatality risk of 1·39% (95% credible interval 1·04-1·77) in New York City. Our estimated infection-fatality risk for the two oldest age groups (65-74 and ≥75 years) was much higher than the younger age groups, with a cumulative estimated infection-fatality risk of 0·116% (0·0729-0·148) for those aged 25-44 years and 0·939% (0·729-1·19) for those aged 45-64 years versus 4·87% (3·37-6·89) for those aged 65-74 years and 14·2% (10·2-18·1) for those aged 75 years and older. In particular, weekly infection-fatality risk was estimated to be as high as 6·72% (5·52-8·01) for those aged 65-74 years and 19·1% (14·7-21·9) for those aged 75 years and older.

Interpretation: Our results are based on more complete ascertainment of COVID-19-related deaths in New York City than other places and thus probably reflect the true higher burden of death due to COVID-19 than that previously reported elsewhere. Given the high infection-fatality risk of SARS-CoV-2, governments must account for and closely monitor the infection rate and population health outcomes and enact prompt public health responses accordingly as the COVID-19 pandemic unfolds.

Funding: National Institute of Allergy and Infectious Diseases, National Science Foundation Rapid Response Research Program, and New York City Department of Health and Mental Hygiene.

Citing Articles

Role of new vaccinators/pharmacists in life-course vaccination.

Doherty T, Privor-Dumm L Ann Med. 2024; 56(1):2411603.

PMID: 39453787 PMC: 11514396. DOI: 10.1080/07853890.2024.2411603.


Spatial scales of COVID-19 transmission in Mexico.

Klein B, Hartle H, Shrestha M, Zenteno A, Barros Sierra Cordera D, Nicolas-Carlock J PNAS Nexus. 2024; 3(9):pgae306.

PMID: 39285936 PMC: 11404565. DOI: 10.1093/pnasnexus/pgae306.


Infectious disease surveillance needs for the United States: lessons from Covid-19.

Lipsitch M, Bassett M, Brownstein J, Elliott P, Eyre D, Grabowski M Front Public Health. 2024; 12:1408193.

PMID: 39076420 PMC: 11285106. DOI: 10.3389/fpubh.2024.1408193.


Inference on spatiotemporal dynamics for coupled biological populations.

Li J, Ionides E, King A, Pascual M, Ning N J R Soc Interface. 2024; 21(216):20240217.

PMID: 38981516 PMC: 11285444. DOI: 10.1098/rsif.2024.0217.


Syndecan-1 as a prognostic biomarker in COVID-19 patients: a retrospective study of a Japanese cohort.

Hayashi K, Koyama D, Hamazaki Y, Kamiyama T, Yamada S, Furukawa M Thromb J. 2024; 22(1):52.

PMID: 38907229 PMC: 11191303. DOI: 10.1186/s12959-024-00619-2.


References
1.
Lasry A, Kidder D, Hast M, Poovey J, Sunshine G, Winglee K . Timing of Community Mitigation and Changes in Reported COVID-19 and Community Mobility - Four U.S. Metropolitan Areas, February 26-April 1, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(15):451-457. PMC: 7755061. DOI: 10.15585/mmwr.mm6915e2. View

2.
Clark A, Jit M, Warren-Gash C, Guthrie B, Wang H, Mercer S . Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020; 8(8):e1003-e1017. PMC: 7295519. DOI: 10.1016/S2214-109X(20)30264-3. View

3.
Havers F, Reed C, Lim T, Montgomery J, Klena J, Hall A . Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020; . DOI: 10.1001/jamainternmed.2020.4130. View

4.
Verity R, Okell L, Dorigatti I, Winskill P, Whittaker C, Imai N . Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; 20(6):669-677. PMC: 7158570. DOI: 10.1016/S1473-3099(20)30243-7. View

5.
Li R, Pei S, Chen B, Song Y, Zhang T, Yang W . Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020; 368(6490):489-493. PMC: 7164387. DOI: 10.1126/science.abb3221. View